Board of Directors
Gordon Baty, Ph.D.
Chairman of the Board
Gordon Baty has over 40 years of experience with early-stage ventures and finance. He has started, managed, merged, sold, financed, studied, advised and on occasion buried, numerous entrepreneurial ventures. He has built a succession of high tech firms and has taught entrepreneurship and venture finance at MIT Sloan School and Northeastern University. He was a founder and managing director at Zero Stage Capital, a venture capital firm specializing in early-stage technology ventures. He also started and served as Chairman of Navigator Technology Ventures, a technology commercialization fund. He currently serves as Chairman at Passport Systems, a company developing technology for the detection of molecular signatures in cargo materials, and served for many years as a board member at Charles Stark Draper Laboratory at MIT. He holds BS, MS and PhD (finance) degrees from MIT.
Jean-Luc Boulnois, E.M.B.A, Ph.D.
Dr. Boulnois has over 30 years of international leadership experience in creating, operating, and financing medical device companies, with which he led several mergers, acquisitions, and financing rounds. Dr. Boulnois is CEO of Quadrature, a strategic advisory firm for MedTech companies. For 11 years Dr. Boulnois has been Chairman and CEO of Microline Surgical, Inc., a worldwide leader in disposable electro-surgical instruments. Previously he served as Venture Partner at Dover Medical Ventures, a Boston-based venture fund; he also has been Executive Director at Arrow International and co-developer and CEO of Sometec, a cardiovascular monitoring company. He previously was President and COO of Technomed International Inc., a urology company listed on the Paris “Second Marché” through an IPO; he also has been Vice-President of Research at Quantel SA where he developed several scientific and medical lasers. Dr. Boulnois served for 4 years on the Princeton University Mechanical and Aerospace Engineering Department Advisory Council; he recently served as Director of a public company listed on the Euronext and now serves on the Board of several venture capital financed private medical device firms in the US and Europe. Dr. Boulnois is co-author of 5 books and more than 35 peer-reviewed scientific articles in applied physics and biophysics; he is an Adjunct Professor at Babson College and previously was a Lecturer at Princeton University. He holds an M.Sc. from Paris University, an E.M.B.A. from HEC in Paris, and a Ph.D. in Mechanical and Aerospace Engineering from Princeton University. Dr. Boulnois is bi-national American and French and has lived for 33 years in the United States.
William Mills has over 38 years of experience in venture capital, having been involved in the creation and development of dozens of science-based medical companies. He currently serves in a non-executive role as Chairman of the Board of Managers of Ascension Ventures IV, L.P., a strategic healthcare venture fund with more than $800 million in capital under management. He retired from Stereotaxis, Inc., a publicly-traded medical device company globally commercializing advanced robotic technologies for the treatment of cardiac arrhythmias, in February 2017, having served as Chief Executive Officer since April 2013 and as Chairman of the Board of Directors since May 2012. His venture capital roles have included serving for five years as a Partner in the Boston office of Advent International, a global private equity and venture capital firm, where he was co-responsible for healthcare venture capital investments and focused on investments in the medical technology and biopharmaceutical sectors. Before joining Advent, Mr. Mills spent more than 11 years with the Venture Capital Fund of New England where he was a General Partner. Prior to that, he spent seven years at PaineWebber Ventures/Ampersand Ventures as Managing General Partner. Mr. Mills received an S.M. in Chemistry from the Massachusetts Institute of Technology, an M.S. in Management from the Massachusetts Institute of Technology Sloan School of Management, and an A.B. cum laude in Chemistry from Princeton University.
Nader Yaghoubi, M.D., Ph.D.
President and Chief Executive Officer
Dr. Yaghoubi has over 20 years of experience in the creation, operations and financing of life science companies. Before his involvement with PathMaker Neurosystems, he established, as President and Founding CEO, Symbiotix Biotherapies, a pioneering microbiome company developing novel molecular therapeutics based on the human microbiome. Prior to Symbiotix, he was the first employee at Selecta Biosciences and BIND Therapeutics (Nasdaq:BIND), where he worked with the founders to launch the companies and establish operations and corporate development. Previously, he was at Zero Stage Capital, a venture capital firm where he was responsible for investing in the life sciences sector, and earlier completed an internship at Advent International. Prior to this, he was a Health Care Entrepreneurship Fellow at Boston University, where he worked with scientists and physicians to develop new businesses in the healthcare and life science sector. Before his fellowship, he was a surgical resident in the Department of Surgery at Lenox Hill Hospital in New York. Dr. Yaghoubi received an M.D. and Ph.D. in Molecular Pharmacology from the combined degree program at Boston University School of Medicine. His doctorate work on the development of high-throughput automated electrophysiological systems resulted in five issued patents, received one of the University’s highest awards for dissertational research, and was the basis of a venture-backed biotechnology company focused on neuroscience. He is extensively involved in mentoring young companies, and has served/serves as a mentor, advisor and reviewer with MBC’s MassCONNECT program, Mass Life Sciences Center programs, Springboard Venture Capital Forum and numerous university business plan competitions.
Jake Maslow, J.D.
Jake Maslow has 30 years of experience in various aspects of entrepreneurialism and IP commercialization, including recognition of innovation and commercial opportunity in new technologies, assisting startups and business formation, managing team formation and strategic growth, fund raising, strategic partnering, high-tech new product development and marketing, university licensing, and corporate and IP law. He was a former Director of the CUNY Technology Commercialization Office and was former Assistant Director of MIT Patents and Technology Licensing Office. Jake has been co-founder of several startups based on technologies out of MIT. As co-founder and CEO of Synkinetics, Inc., Jake successfully built a high-tech engineering company based on a proprietary high precision drive system for industrial and military applications, securing sponsorship of several leading F-500 companies, and supported by 30 angel investors, while generating substantial federal and commercial grants and revenues. As Co-founder and IP counsel / Strategic Advisor of Sionex Corporation, Jake introduced successful VC investment to support development of state-of-the-art lab-on-a-chip for real-time chemical detection; while working closely with C-level engineering and marketing to build substantial IP portfolio and to secure market entry; He is a graduate of Columbia University (CC’73, PS) and Brooklyn Law School (Juris Doctorate ‘76), and is a member of the New York and Massachusetts Bar and a registered US patent attorney. Jake also is an Air Force veteran, having graduated USAF Radar Electronics School (1968) and served as radar technician for the F4 Phantom Jet.